Replies to post #191 on Oncolytics Biotech Inc. (ONCY)

[DFRAI]

Onco

i found some papers on H&N for paclitaxel and carboplatin

1. 31 patients with local advanced cancer, metastatic or relapsed SCCHN

ORR was 52% (1 CR and 16 patients with PR), PFS 5.4 months, median overall survival 12.8 months

2. 27 patients, metastatic cancer

ORR was 59% (11% CR, 48% PR and 19% SD), , no PFS given

Reolysin results in H&N with paclitaxel and carboplatin

3. 19 patients, metastatic cancer and refractory to platinum treatments

ORR was 42% (PR 42% and SD 32%)(ONCY was counting SD and boosting ORR to 75% - is this misleading?, PFS and OS to be presented


I guess its difficult to compare results without the so called randomized trials. Not sure of it anymore.